EPCAM and hepatocellular carcinoma: Several clinical trials are under recruitment to evaluate the efficacy and safety of EpCAM CAR T cells in patients with advanced HCC or in cases of postoperative relapse, as well as in refractory HCC (NCT02729493, NCT03013712, NCT05028933).